Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital
Response rates and overall survival from this real-world cohort are comparable to previously published contemporary studies. The high complete response rate, 5-year progression-free survival, and 5-year overall survival in this study further support the robust curative potential of doxorubicin + bleomycin + vinblastine + dacarbazine and validate its continued use in resource-limited settings.
Authors
- Eugene Chao
- Sarah Tomassetti (ORCID: https://orcid.org/0000-0001-6087-8788)
- Joseph P. Marshalek (ORCID: https://orcid.org/0000-0002-7362-3909)
- David Yashar
Institutions
- UCLA Medical Center (US)
- Harbor–UCLA Medical Center (US)
Publication Details
- Journal
- SAGE Open Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1177/20503121251365462
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00